Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy

Biesaga, Beata; Niemiec, Joanna; Ziobro, Marek; Wysocka, Joanna; Kruczak, Anna

doi:10.1016/j.breast.2011.03.002

Cited by 9 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All details regarding immunohistochemical staining of estrogen (ER) and progesterone receptors (PgR), cytokeratin 5/6 (CK5/6), HER2+, TOPOIIα LI, MVD, P53 labelling index (P53 LI), and BCL-2 expression were described in our earlier papers [2,13,14]. On the basis of ER, PgR and HER2 expression, we identified BC immunophenotypes: …”

Section: Immunohistochemistrymentioning

confidence: 98%

“…In this analysis, we additionally included other parameters, which were tested in our earlier papers [2,13,14] and which significantly affected DFS in univariate analysis (i.e., grade, the status (positive vs negative) of ER, PgR, CK5/6, overexpression or not of TOPOIIα LI, P53 LI, and BCL-2 as well as MVD and BC immunophenotypes (LA + LB vs HER2+ and TN)) ( Table 4). This analysis confirmed our earlier results that topoisomerase IIα, microvessel density, and BCL-2 expression are independent prognostic factors for adjuvant chemotherapy based on anthracyclines [2].…”

Section: Apoptosis Level Proliferation Rate and Correlations With Cmentioning

confidence: 99%

“…All women obtained adjuvant chemotherapy with ATC according to two schedules: (i) six or four cycles of FAC (5-fluorouracil, doxorubicin, cyclophosphamide) (40.1 % of patients), and (ii) six or four cycles of AC (doxorubicin, cyclophosphamide) (59.9 % of patients). All other details concerning clinical data were described in our earlier papers [2,13,14].…”

Section: Patientsmentioning

confidence: 99%

“…To the best of our knowledge, there are no data concerning prognostic value of apoptosis level for adjuvant ATC-based chemotherapy in patients with BC. Therefore, in the present paper, we decided to analyze prognostic potential of apoptosis level measured by terminal deoxynucleotidyl transferase dUTP nick end labelling assay (TUNEL) in the same patient cohort (172 women with BC in clinical stage T1-T2, N1-N2, MO, all treated with adjuvant chemotherapy with ATC) as earlier [2,13,14]. Moreover, because cancer growth is determined by the proportion of proliferating to dying cells into the tumor, we decided also to analyze prognostic potential of BC proliferation rate.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings

et al. 2015

Self Cite

View full text Add to dashboard Cite

Cancer growth is determined by the proportion of proliferating to dying cells; thus, the aim of the study was to analyze how proliferation rate and apoptosis level affect disease-free survival (DFS) of breast cancer (BC) patients treated with anthracycline-based chemotherapy. For 172 BC, proliferation rate was investigated by Ki-67 labeling index (Ki-67 LI)-assessed immunohistochemically. Apoptosis level was analyzed by apoptotic index (AI) estimated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. To stratify patients into subgroups with higher and lower DFS and to achieve optimal categorization, optimal cutoff points were searching by minimal P value method. The best separation of DFS curves (P = 0.001) was observed for three categories of AI: (i) AI >1.8 % (DFS = 100 %), (ii) AI ≤0.3 % (DFS = 84.6 %), and (iii) 1.8 % <= AI >0.3 % (DFS = 64.0 %). The highest DFS (86.1 %) was shown for the subgroup with low-proliferating BC (Ki-67 LI ≤18.0 %), intermediate (73.9 %) for patients characterized by Ki-67 LI in the range 18.0-37.0 % and the lowest (60.0 %) for women with fast-proliferating tumors (Ki-67 LI >37.0 %) (P = 0.022). Summarized, minimal P value method allows for optimal separation of survival curves. Apoptosis level and proliferation rate have some prognostic potential for early stage breast cancer patients treated with anthracyclines in adjuvant setting, however, as suggested by multivariate analysis, not as independent prognostic factors.

show abstract

Section: Immunohistochemistrymentioning

confidence: 98%

Section: Apoptosis Level Proliferation Rate and Correlations With Cmentioning

confidence: 99%

Section: Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, with validated predictive biomarkers for anthracycline sensitivity/resistance, it would be possible to direct the toxic anthracycline treatment to those patients with the highest likelihood of a treatment benefit. 5 Recently; topoisomerase IIa (TOP2a) and tissue inhibitor of metalloproteinases 1 (TIMP-1) are among the novel predictive biomarkers for anthracycline sensitivity.…”

mentioning

confidence: 99%

The Predictive and Prognostic Role of Topoisomerase IIα and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy

Rebey

Aiad²,

Abulkheir³

et al. 2016

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

show abstract

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy

Biesaga¹,

Niemiec²,

Ziobro

2014

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose The aim of this retrospective study was to investigate the effect of B cell lymphoma 2 (BCL-2) expression on disease-free survival (DFS) in 172 early breast cancer (BC) patients treated with anthracycline-based adjuvant chemotherapy. We have reanalysed follow-up data in these patient groups, and therefore, the relation between DFS and other tumour biological features [expression of oestrogen (ER) and progesterone (PgR) receptors, cytokeratin 5/6 (CK5/6), HER2, topoisomerase IIα (TOPOIIα), Ki-67, P53 and microvessel density (MVD)] studied previously (Biesaga et al. in Breast 20(4):338–350, 2011, doi:10.1016/j.breast.2011.03.002, Pathol Oncol Res 18(4): 949–960, 2012, doi:10.1007/s12253-012-9525-9) was also investigated.MethodTumour biological features were assessed immunohistochemically on paraffin-embedded sections obtained before treatment from 172 women with BC in stage T1–T2, N1–N2, M0.ResultsIn univariate analysis, longer DFS was found for patients having tumours with BCL-2 positivity (P = 0.005), low grade (P = 0.001), ER (P = 0.017) and PgR (P = 0.045) positivity, CK5/6 negativity (P = 0.021), low TOPOIIα expression (P = 0.003) and high MVD (P = 0.000). In multivariate analysis, BCL-2, TOPOIIα and MVD were independent parameters indicating patient prognosis. All patients (n = 18) characterized by tumour BCL-2 positivity, low TOPOIIα expression and high MVD survived 80 months without any evidence of cancer disease, whereas DFS for all other patients was significantly (P = 0.022) lower (76.5 %).ConclusionCombination of three parameters: BCL-2 positivity, low topoisomerase IIα expression and high MVD, allows to identify subgroup of BC patients with very good prognosis after adjuvant anthracycline-based chemotherapy.

show abstract

Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy

Abstract: The results suggest that lower TOPOIIα expression and lower tumour grade are favourable prognostic factors for early advanced breast cancer patients after adjuvant anthracycline chemotherapy.

Cited by 9 publications

References 30 publications

The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings

The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings

The Predictive and Prognostic Role of Topoisomerase IIα and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy

BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy

Contact Info

Product

Resources

About